Sugi Predict

Sugi Predict / Targets / KDM4D

KDM4D

Lysine-specific demethylase 4D · Q6B0I6 · KDM4D on Sugi Atlas →

17,286 patent compounds predicted against KDM4D, 8,834 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL613091 SCHEMBL613091 0.44 19/20
SCHEMBL319153 SCHEMBL319153 0.40 7/20
SCHEMBL1023235 SCHEMBL1023235 0.61 5/20
SCHEMBL82604 SCHEMBL82604 0.59 5/20
SCHEMBL480991 SCHEMBL480991 0.59 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1027857) 0.57 5/20
SCHEMBL894396 SCHEMBL894396 0.56 5/20
SCHEMBL1643182 SCHEMBL1643182 0.56 5/20
SCHEMBL116060 SCHEMBL116060 0.55 5/20
SCHEMBL535637 SCHEMBL535637 0.55 5/20
SCHEMBL547927 SCHEMBL547927 0.55 5/20
SCHEMBL258224 SCHEMBL258224 0.53 5/20
SCHEMBL1456142 SCHEMBL1456142 0.50 5/20
SCHEMBL1569204 SCHEMBL1569204 0.50 5/20
SCHEMBL1337530 SCHEMBL1337530 0.44 5/20
SCHEMBL461147 SCHEMBL461147 0.41 5/20
SCHEMBL393733 SCHEMBL393733 0.34 5/20
SCHEMBL535569 SCHEMBL535569 1.00 4/20
SCHEMBL71335 SCHEMBL71335 0.65 4/20
SCHEMBL115797 SCHEMBL115797 0.59 4/20

Clinical trials — most relevant to KDM4D by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients PHASE1UNKNOWN
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
The Danish TURNER Cryopreservation Study nanRECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Role of Genomic Imprinting in Cancer Diagnosis nanUNKNOWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM4D binder may also engage these)

ProteinNameSimilarity
KDM4E Lysine-specific demethylase 4E 0.999 landscape →
Q3U2K5 — 0.998 Q3U2K5 →
A0A1W2PPD8 — 0.996 A0A1W2PPD8 →
A1A5Q5 — 0.995 A1A5Q5 →
KDM4B Lysine-specific demethylase 4B 0.993 landscape →
D3YWQ0 — 0.989 D3YWQ0 →
Q5TKR9 — 0.989 Q5TKR9 →
Q9V333 — 0.989 Q9V333 →
Q8VCD7 — 0.988 Q8VCD7 →
Q8BMD7 — 0.988 Q8BMD7 →
Q91VY5 — 0.987 Q91VY5 →
Q9V6L0 — 0.986 Q9V6L0 →
Q8BW72 — 0.986 Q8BW72 →
Q5RD88 — 0.986 Q5RD88 →
Q9UPV7 — 0.986 Q9UPV7 →
Q3ULB5 — 0.985 Q3ULB5 →
F1MAB7 — 0.985 F1MAB7 →
KDM5D Lysine-specific demethylase 5D 0.985 landscape →
Q6EEF3 — 0.985 Q6EEF3 →
Q9BQK8 — 0.985 Q9BQK8 →
P03177 — 0.985 P03177 →
Q3V1D5 — 0.985 Q3V1D5 →
Q63553 — 0.985 Q63553 →
Q8BWQ5 — 0.985 Q8BWQ5 →
KDM5B Lysine-specific demethylase 5B 0.985 landscape →
Q8BZ21 — 0.985 Q8BZ21 →
KAT6B Histone acetyltransferase KAT6B 0.985 landscape →
Q5ZLK6 — 0.985 Q5ZLK6 →
Q28314 — 0.985 Q28314 →
P59729 — 0.985 P59729 →